February 14, 2007 -- Osiris reported that Chondrogen, a stem cell treatment, was not effective in regenerating meniscus in the knee, but it did rebuild cartilage and improve joint condition; Invitrogen sold its BioReliance contract research division for $210 million; Telik fired 25% of its workforce; Advancis said the FDA rejected its NDA for once-daily Amoxicillin Pulsys; GW Pharma sold the US rights to its cannabis-based pain drug to Japan’s Otsuka Pharma; Merck disclosed that 28 cases of intussusception occurred in infants and children receiving Rotateq; Peregrine reported its hepatitis C drug was safe and well-tolerated; Infinity and MedImmune began a Phase I/II trial of a new cancer drug; Halozyme and Baxter reached a deal to use Hylenex; Favrille will collaborate with Berlex to combine FavID and Leukine; Rosetta Genomics will make another run at its long-delayed IPO; and Biohart made its initial IPO filing. The Centient Biotech 200™ rose 34 points to 4074, an increase of .85%. More details...
